United TherapeuticsFRA:UTH -2.65%84 Median PS Value is €285.63 as of Jun. 29, 2026, which is 100% below its 10-year median of 1.03. GuruFocus rates FRA:UTH with a GF Score™ of 84/100 and a GF Value™ of €337.25 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 544 Drug Manufacturers companies, United Therapeutics ranks worse than 87.32% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for United Therapeutics's Median PS Value or its related term are showing as below:
FRA:UTH'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55 Med: 1.03 Max: 1.81
Current: 1.66
During the past 13 years, the highest Price to Median PS Value of United Therapeutics was 1.81. The lowest was 0.55. And the median was 1.03.
FRA:UTH's Price-to-Median-PS-Value is ranked worse than 87.32% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.85
vs FRA:UTH: 1.66
United Therapeutics (FRA:UTH) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
United Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
473.30
/
285.63
=
1.66
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics Median PS Value Related Terms
United Therapeutics Median PS Value Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UTH vs VTRS, NBIX, ZTS: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 4.9826.
United Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €57.325.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (FRA:UTH) has a Median PS Value of €285.63 as of Jun. 29, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on United Therapeutics and its competitors. This is 27631% above median its historical median of 1.03. Over the past decade, United Therapeutics' Median PS Value has ranged from 0.55 to 1.81. According to the industry distribution chart, United Therapeutics ranks #475 out of 544 companies in the Drug Manufacturers industry, placing it in the top 87.3%.
Is United Therapeutics' Median PS Value too high?
United Therapeutics' current Median PS Value of €285.63 is 27631% above median its 10-year median of 1.03. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 1.81. Based on the distribution chart, United Therapeutics ranks #475 out of 544 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, United Therapeutics has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Median PS Value compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #475 out of 544 companies for Median PS Value. This places United Therapeutics in the lower half of its industry. The industry median Median PS Value is 0.85. Historically, United Therapeutics' own Median PS Value has ranged from 0.55 to 1.81 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.85, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current Median PS Value is €285.63, which is 27631% above median its own 10-year median of 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (FRA:UTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €337.25, compared to a current price of €473.30 — trading 40.3% above its estimated fair value. The current Median PS Value is €285.63, which is 27631% above median its 10-year median of 1.03. United Therapeutics' overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For United Therapeutics (FRA:UTH), the current Median PS Value is €285.63 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (FRA:UTH) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of €473.30 is trading 40.3% above its estimated GF Value™ of €337.25.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:UTH:
Median PS Value: €285.63 (27631% above median its 10-year median of 1.03)
GF Value™: €337.25 vs. price of €473.30 (40.3% above fair value)
No single metric tells the full story. See the FRA:UTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
84GF Score
Get the complete analysis for FRA:UTH
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UTH has been successfully added to your 
